Sera Prognostics Inc Class A SERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
-
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
-
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
-
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
-
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
-
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
-
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
Trading Information
- Previous Close Price
- $2.06
- Day Range
- $1.94–2.05
- 52-Week Range
- $1.56–3.95
- Bid/Ask
- $1.91 / $2.11
- Shares Outstanding
- 39.16M
- Market Cap
- $77.14M
- Volume/Avg
- 15,857 / 49,066
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,788.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 72
- Website
- https://www.seraprognostics.com
Valuation
|
Metric
|
SERA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.19 |
Price/Sales | 1,788.83 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SERA
|
|---|---|
Quick Ratio | 2.02 |
Current Ratio | 2.12 |
Interest Coverage | −5,200.29 |
Quick Ratio
SERA
Profitability
|
Metric
|
SERA
|
|---|---|
Return on Assets (Normalized) | −25.94% |
Return on Equity (Normalized) | −33.91% |
Return on Invested Capital (Normalized) | −38.36% |
Return on Assets
SERA
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|%D^Cjv | LOCK|S<&pQ | $164B | |||
| Stryker Corp
SYK
| LOCK|&Vrj#X^J | LOCK|?Xx | $126B | |||
| Medtronic PLC
MDT
| LOCK|%V?Mw^X | LOCK|!?kd | $107B | |||
| Boston Scientific Corp
BSX
| LOCK|D@PG!C | LOCK|QJ%< | $67B | |||
| Edwards Lifesciences Corp
EW
| LOCK|##GC^??& | LOCK|Y#@Z | $53B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|qQS&dD | LOCK|L&# | $29B | |||
| DexCom Inc
DXCM
| LOCK|y&K?^ZxP | LOCK|FpCB< | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|<p | LOCK|Zx< | $27B | |||
| Steris PLC
STE
| LOCK|rMRG$C^ | LOCK|bt&^ | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|%!M@^F% | LOCK|<n# | $18B |
United States